Trial Profile
A three-week inpatient study of albenatide [PC-DAC:Exendin-4 ] in patients with type 2 diabetes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Mar 2015
Price :
$35
*
At a glance
- Drugs Albenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors ConjuChem
- 27 Mar 2015 New trial record